Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Research in MicroRNA Profiling of Prostate Cancer
share announcement

Research in MicroRNA Profiling of Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 6847

Special Issue Editors

Prof. Dr. Palle Jörn Sloth Osther

E-Mail Website
Guest Editor
Department of Urology, Vejle Hospital (Lillebaelt Hospital), University Hospital of Southern Denmark, 7100 Vejle, Denmark
Interests: prostate cancer; UTUC; endourology; kidney calculi; communication in health care
Special Issues, Collections and Topics in MDPI journals
Dr. Ahmed H. Zedan

E-Mail
Guest Editor
Department of Oncology, Vejle Hospital – a part of Lillebaelt Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark
Interests: Prostate Cancer; Biomarkers; Translational and Interventional studies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in males in the West. Prostate-specific antigen (PSA) is the major serum biomarker used for the detection and monitoring of PCa progression. Nevertheless, its prognostic value is limited in diagnosis and monitoring of treatment due to low sensitivity and specificity.

MicroRNAs (miRNAs) seem to be quite promising alternative biomarkers in this context. The evidence suggests that miRNAs may play a crucial role in malignant transformation, tumor growth, and spread. Studies have shown that miRNAs are expressed abnormally in various cancers, suggesting that they play a pivotal role in cancer development and progression. The importance of miRNAs in the development of PCa has been illustrated by a series of interactions between miRNA and mRNA influencing carcinogenesis. It is assumed that dysregulated miRNAs are important for altered cell growth and invasion and thus may be crucial for the metastatic potential of PCa. However, the exact role of PCa-specific miRNAs for prevention, diagnosis, and treatment of PCa needs to be clarified.

This Special Issue will highlight the role of miRNAs in PCa, with an overview of various potential candidate miRNAs in different stages of the disease.

Prof. Dr. Palle Jörn Sloth Osther
Dr. Ahmed H. Zedan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA
  • prostate cancer
  • radiotherapy
  • prostatectomy
  • chemotherapy
  • mCRPC
  • new hormonal agents
  • prognostic biomarker
  • qPCR
  • ISH

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 2976 KiB  
Review
MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development
by Wen (Jess) Li, Xiaozhuo Liu, Emily M. Dougherty and Dean G. Tang
Cancers 2022, 14(18), 4538; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14184538 - 19 Sep 2022
Cited by 6 | Viewed by 2488
Abstract
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in PCa has been observed for decades, from untreated tumors to castration-resistant prostate cancer (CRPC) to disseminated metastases. Current standard-of-care [...] Read more.
Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in PCa has been observed for decades, from untreated tumors to castration-resistant prostate cancer (CRPC) to disseminated metastases. Current standard-of-care therapies for metastatic CRPC can only extend life by a few months. Cancer stem cells (CSCs) are defined as a subpopulation of cancer cells that exists in almost all treatment-naive tumors. Additionally, non-CSCs may undergo cellular plasticity to be reprogrammed to prostate cancer stem cells (PCSCs) during spontaneous tumor progression or upon therapeutic treatments. Consequently, PCSCs may become the predominant population in treatment-resistant tumors, and the “root cause” for drug resistance. microRNA-34a (miR-34a) is a bona fide tumor-suppressive miRNA, and its expression is dysregulated in PCa. Importantly, miR-34a functions as a potent CSC suppressor by targeting many molecules essential for CSC survival and functions, which makes it a promising anti-PCSC therapeutic. Here, we conducted a comprehensive literature survey of miR-34a in the context of PCa and especially PCSCs. We provided an updated overview on the mechanisms of miR-34a regulation followed by discussing its tumor suppressive functions in PCa. Finally, based on current advances in miR-34a preclinical studies in PCa, we offered potential delivery strategies for miR-34a-based therapeutics for treating advanced PCa. Full article
(This article belongs to the Special Issue Research in MicroRNA Profiling of Prostate Cancer)
►▼ Show Figures

Figure 1

19 pages, 701 KiB  
Review
Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review
by Giulia Corrao, Mattia Zaffaroni, Luca Bergamaschi, Matteo Augugliaro, Stefania Volpe, Matteo Pepa, Giuseppina Bonizzi, Salvatore Pece, Nicola Amodio, Francesco Alessandro Mistretta, Stefano Luzzago, Gennaro Musi, Sarah Alessi, Francesco Maria La Fauci, Chiara Tordonato, Daniela Tosoni, Federica Cattani, Sara Gandini, Giuseppe Petralia, Gabriella Pravettoni, Ottavio De Cobelli, Giuseppe Viale, Roberto Orecchia, Giulia Marvaso and Barbara Alicja Jereczek-Fossaadd Show full author list remove Hide full author list
Cancers 2021, 13(13), 3278; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133278 - 30 Jun 2021
Cited by 7 | Viewed by 3206
Abstract
In recent years, a growing interest has been directed towards oligometastatic prostate cancer (OMPC), as patients with three to five metastatic lesions have shown a significantly better survival as compared with those harboring a higher number of lesions. The efficacy of local ablative [...] Read more.
In recent years, a growing interest has been directed towards oligometastatic prostate cancer (OMPC), as patients with three to five metastatic lesions have shown a significantly better survival as compared with those harboring a higher number of lesions. The efficacy of local ablative treatments directed on metastatic lesions (metastases-directed treatments) was extensively investigated, with the aim of preventing further disease progression and delaying the start of systemic androgen deprivation therapies. Definitive diagnosis of prostate cancer is traditionally based on histopathological analysis. Nevertheless, a bioptic sample—static in nature—inevitably fails to reflect the dynamics of the tumor and its biological response due to the dynamic selective pressure of cancer therapies, which can profoundly influence spatio-temporal heterogeneity. Furthermore, even with new imaging technologies allowing an increasingly early detection, the diagnosis of oligometastasis is currently based exclusively on radiological investigations. Given these premises, the development of minimally-invasive liquid biopsies was recently promoted and implemented as predictive biomarkers both for clinical decision-making at pre-treatment (baseline assessment) and for monitoring treatment response during the clinical course of the disease. Through liquid biopsy, different biomarkers, commonly extracted from blood, urine or saliva, can be characterized and implemented in clinical routine to select targeted therapies and assess treatment response. Moreover, this approach has the potential to act as a tissue substitute and to accelerate the identification of novel and consistent predictive analytes cost-efficiently. However, the utility of tumor profiling is currently limited in OMPC due to the lack of clinically validated predictive biomarkers. In this scenario, different ongoing trials, such as the RADIOSA trial, might provide additional insights into the biology of the oligometastatic state and on the identification of novel biomarkers for the outlining of true oligometastatic patients, paving the way towards a wider ideal approach of personalized medicine. The aim of the present narrative review is to report the current state of the art on the solidity of liquid biopsy-related analytes such as CTCs, cfDNA, miRNA and epi-miRNA, and to provide a benchmark for their further clinical implementation. Arguably, this kind of molecular profiling could refine current developments in the era of precision oncology and lead to more refined therapeutic strategies in this subset of oligometastatic patients. Full article
(This article belongs to the Special Issue Research in MicroRNA Profiling of Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop